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ABSTRACT 
Background: Intravenous aminoglycoside antibiotics are widely used to treat 
pulmonary infection with Pseudomonas aeruginosa in individuals with cystic 
fibrosis (CF). Over the last decade evidence has accumulated showing that 
the choice of aminoglycoside and the dosing regimen may help reduce 
adverse effects such as nephrotoxicity.  
Methods: We undertook an online survey to determine current practice in UK 
CF Centres.  
Results: We received a response from 35/48 (73%) centres. A once daily 
regimen was used in 30/35 (86%) centres. Around one third had stopped 
using gentamicin in the last 10 years. In most cases respondents reported 
changing practice in response to new evidence or evidence based guidelines. 
Obstacles to introducing evidence based practice were identified both at the 
level of the CF Centre and the hospital trust.  
Conclusions: A once daily aminoglycoside regimen is now used in the 
majority of UK CF Centres. Tobramycin is first line and many centres have 
stopped using gentamicin. Obstacles to evidence based practice remain in a 
minority of centres. 
 
Key words: Cystic fibrosis; aminoglycosides; nephrotoxicity; once daily 
dosing; obstacles to evidence based practice. 
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INTRODUCTION 
 
Aminoglycoside antibiotics are widely used for the management of pulmonary 
exacerbations in cystic fibrosis (CF) due to Pseudomonas aeruginosa. In the 
UK around one third of CF patients receive intravenous antibiotics in a year, 
for a median of 23 days[1]. Aminoglycosides are recommended as first line 
therapy[2] and so CF patients are vulnerable to adverse effects, such as 
nephrotoxicity. The risk of acute kidney injury (AKI) is greater in CF than in the 
general population (100 times greater in children) and most episodes are 
related to aminoglycosides[3]. There are a limited number of antibiotics which 
are active against P. aeruginosa and so clinicians will continue to use 
intravenous aminoglycosides. However there is good evidence that 
nephrotoxicity may be reduced by using a once daily regimen[4] and by 
avoiding the use of gentamicin[3]. This evidence has informed 
recommendations in treatment guidelines both in the UK[2] and the US[5]. 
Indeed the guideline recommendation on aminoglycoside use has been 
highlighted as one of the few which is evidence based[5]. We therefore chose 
to evaluate adherence to this recommendation as an example of guideline 
adherence in CF. A decade ago, we conducted a survey of aminoglycoside 
prescribing practices in UK CF centres which showed low uptake of these 
strategies[6]. We wanted to know whether practice has changed in the light of 
evidence from recent research and so we repeated this survey. 
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METHODS 
We contacted the Centre Director for all UK CF centres by email (using a 
contact list provided by the UK Cystic Fibrosis Trust) and invited them to 
complete an online questionnaire (figure 1) which asked about 
aminoglycoside prescribing practices in their centre. Answers could be yes / 
no; choose one option; choose one or more options; or free text, depending 
on the context of the question. Invitation emails were sent in March 2013 and 
a follow up to non-responders was sent a month later. The online tool 
captured the email address of the respondent and so duplicate responses 
from the same centre could be identified. Where there was more than one 
response from the same centre, we used the first response only. The 
questionnaire (Q1-3) asked specifically about first line antibiotic therapy for P. 
aeruginosa (the commonest indication for aminoglycosides in CF). This was 
to avoid confusion with aminoglycosides given for other indications such as 
intravenous amikacin for infection with Mycobacterium abscessus, where a 
twice or three times daily regimen is recommended[2]. 
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RESULTS 
We received a response from 35/48 (73%) centres, of which 21/35 (60%) 
were paediatric and 14/35 (40%) adult. Replies came from centres in 
England, Scotland, Wales and Northern Ireland. All centres reported using an 
aminoglycoside as part of an intravenous antibiotic regimen for infection with 
P. aeruginosa (Q1) and all named tobramycin as their first line 
aminoglycoside (Q2).  
 
Results for Q3-Q9 by paediatric and adult centre separately are given in table 
1. A once daily aminoglycoside regimen was used by 30/35 (86%) centres; 
twice daily by 1/35 (3%), and three times daily by 4/35 (11%) (Q3). Twenty 
two centres said they had changed the dosing regimen for aminoglycosides in 
the last 10 years (Q4). Of these, 21 centres had changed from a three times 
daily regimen to once daily, and one centre had changed from three times 
daily to a twice daily regimen (Q5). When asked the reason for changing (Q6), 
19 respondents cited the TOPIC study[7], 5 respondents the UK CF Trust 
Antibiotic Guidelines[2] and 2 gave other reasons (such as local laboratory 
data).  
 
When asked if the specific aminoglycoside drug prescribed in the centre had 
changed in the last 10 years (Q7), 10/35 (29%) centres said they had made a 
change and 24/35 (69%) had not. (One did not reply to this question). Of the 
10 centres who had changed the antibiotic used, all had stopped using 
gentamicin (Q8). The CF Trust Antibiotic Guidelines[2] were cited by 5 centres 
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as a reason for changing; the UK case control study of acute kidney injury[3] 
by 3 centres and 2 gave other reasons (Q9). 
 
We received 11 free text responses (9 from paediatric centres) to Q10 “If you 
have tried to change your aminoglycoside or regimen, but have encountered 
difficulties, please describe these briefly in the box”. Many of these were 
informative, raising issues which fell into the following themes (direct 
quotations from respondents have been used to illustrate these themes). 
Some respondents gave more than one reason. 
• Training issues (3 respondents). “Lots of delays when changing from 
TDS to OD Tobramycin due the training of nurses and parents…” 
• Difficulty arranging infusions (3 respondents). A once daily 
aminoglycoside dose is administered by infusion (usually over 30 
minutes) whereas three times daily doses may be given by bolus. 
“Problems with od antibiotics infusion in the community setting.” 
• Laboratory unwilling to provide tobramycin assay for monitoring 
plasma levels (4 respondents). “Lab will only run a gentamicin and 
not a tobramycin assay. They have agreed to send away tobra levels” 
• Once daily prescribing for CF patients would be out of line with 
policies for other patients increasing the risk of a drug error (1 
respondent). “Hospital policy for other aminoglycosides is 8 hourly - 
we discussed TOPIC findings several times but we felt that clinical risk 
of Tobra overdose to CF patients (receiving once daily) on same ward 
as medical patients (receiving TDS aminoglycosides) would be too 
great.”  
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DISCUSSION 
We have shown a profound change in aminoglycoside prescribing practices, 
in UK CF Centres, over the last decade. At the time of our previous survey[6] 
a once daily aminoglycoside dosing regimen was used in 17% of UK CF 
Centres. Once daily dosing is now used in 86% of centres. The use of 
tobramycin has increased from 87% in our previous survey to its use in all 
centres currently. Just under one third of centres responding had stopped 
using gentamicin in the last 10 years. Appropriately, most respondents cite 
high quality evidence or evidence based guidelines as their reason for 
changing practice. Obstacles to implementing evidence based practice 
include practical issues (such as the need for an infusion device and training). 
However the need for hospital wide change (in the assay performed and in 
the use of once daily regimens in other patients) was a significant obstacle in 
some centres. This is disappointing, as the evidence suggests that a once 
daily regimen should be widely used amongst all patients receiving 
aminoglycosides (not just those with CF) - with few contraindications[8].  
 
Our findings are in line with reported changes in practice in Australia which 
have shown an increase in once daily dosing from 54% in 1999[9] to 88% in 
2009[10]. There are no recent surveys from the US, but once daily 
aminoglycoside dosing is now recommended in US CF Foundation Guidelines 
for managing pulmonary exacerbations[5]. 
 
Whilst our response rate was good (73% centres), 13 centres did not respond 
and it is possible that there was a systematic bias in the non-responders 
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(such as centres not following evidence based practice not wishing to 
respond). The qualitative data reported here are informative but are limited by 
the study design (an online questionnaire). Further valuable data, regarding 
obstacles  to implementing evidence based practice, could be obtained from 
semi-structured interviews with key decision makers in UK CF Centres and 
their hospital trusts. 
 
In the setting of a clinical trial, once daily aminoglycoside dosing for 
pulmonary exacerbations of CF results in less nephrotoxicity[7]. Whether the 
widespread adoption of a safer regimen in the UK will result in fewer cases of 
acute kidney injury amongst CF patients is not known. However, data on 
acute kidney injury, requiring dialysis, are recorded in the UK CF Registry, 
allowing trends to be monitored. Therefore it may become clear over the 
coming years if morbidity has been reduced in this vulnerable group of 
patients. 
 
  
 9 
ACKNOWLEDGEMENTS 
The authors would like to thank all the UK CF Centre Directors who 
completed the questionnaire and the UK Cystic Fibrosis Trust for providing 
contact details for the CF Centres.  
 
CONFLICT OF INTEREST STATEMENT 
ARS was the chief investigator of the TOPIC study and the case control study 
of aminoglycoside use and acute kidney injury in CF. ELC is employed as an 
Impact Researcher at the University of Nottingham. 
 
ROLE OF THE FUNDING SOURCE 
 
Both authors are employed by the University of Nottingham. No additional 
funding was obtained. The authors were exclusively responsible for the study 
design; collection, analysis and interpretation of data; writing the manuscript; 
and the decision to submit the manuscript for publication.  
  
 10 
REFERENCES 
 
[1] UK Cystic Fibrosis Trust. UK CF Registry. Annual Data Report 2011. Bromley: Cystic 
Fibrosis Trust; 2013. 
[2] Antibiotic Treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic 
Group. London: UK Cystic Fibrosis Trust; 2009. 
[3] Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case-control study of 
acute renal failure in patients with cystic fibrosis in the UK. Thorax. 2008;63:532-5. 
[4] Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous 
aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2012:Issue 2. Art. No.: 
CD002009. DOI: 10.1002/14651858.CD002009.pub4. 
[5] Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic 
Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am J Respir Crit 
Care Med. 2009;180:802-8. 
[6] Tan KHV, Hyman-Taylor P, Mulheran M, Knox A, Smyth A. To the editor: Lack of 
concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis 
centers. Pediatr Pulmonol. 2002;33:165. 
[7] Smyth A, Tan KHV, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once 
versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of 
cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet. 2005;365:573-8. 
[8] Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of 
aminoglycosides: a meta-analysis. BMJ. 1996;312:338-45. 
[9] Phillips JA, Bell SC. Aminoglycosides in cystic fibrosis: a descriptive study of current 
practice in Australia. Intern Med J. 2001;31:23-6. 
[10] Soulsby N, Bell S, Greville H, Doecke C. Intravenous aminoglycoside usage and 
monitoring of patients with cystic fibrosis in Australia. What's new? Intern Med J. 
2009;39:527-31. 
 
 
